174 related articles for article (PubMed ID: 26857864)
21. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.
Smith MJ; Beetz C; Williams SG; Bhaskar SS; O'Sullivan J; Anderson B; Daly SB; Urquhart JE; Bholah Z; Oudit D; Cheesman E; Kelsey A; McCabe MG; Newman WG; Evans DG
J Clin Oncol; 2014 Dec; 32(36):4155-61. PubMed ID: 25403219
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
Korshunov A; Sahm F; Stichel D; Schrimpf D; Ryzhova M; Zheludkova O; Golanov A; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2018 Aug; 136(2):303-313. PubMed ID: 29569031
[TBL] [Abstract][Full Text] [Related]
23. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
24. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
25. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age.
Brugières L; Remenieras A; Pierron G; Varlet P; Forget S; Byrde V; Bombled J; Puget S; Caron O; Dufour C; Delattre O; Bressac-de Paillerets B; Grill J
J Clin Oncol; 2012 Jun; 30(17):2087-93. PubMed ID: 22508808
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
27. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
29. Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort.
Kloth K; Obrecht D; Sturm D; Pietsch T; Warmuth-Metz M; Bison B; Mynarek M; Rutkowski S
Front Oncol; 2021; 11():756025. PubMed ID: 34888241
[TBL] [Abstract][Full Text] [Related]
30. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
31. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline.
Pietsch T; Haberler C
Clin Neuropathol; 2016; 35(6):344-352. PubMed ID: 27781424
[TBL] [Abstract][Full Text] [Related]
32. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.
McManamy CS; Pears J; Weston CL; Hanzely Z; Ironside JW; Taylor RE; Grundy RG; Clifford SC; Ellison DW;
Brain Pathol; 2007 Apr; 17(2):151-64. PubMed ID: 17388946
[TBL] [Abstract][Full Text] [Related]
33. Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
Gururangan S; Robinson G; Ellison DW; Wu G; He X; Lu QR; McLendon R; Grant G; Driscoll T; Neuberg R
Pediatr Blood Cancer; 2015 Oct; 62(10):1855-8. PubMed ID: 25940061
[TBL] [Abstract][Full Text] [Related]
34. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study.
McLendon RE; Friedman HS; Fuchs HE; Kun LE; Bigner SH
Histopathology; 1999 Feb; 34(2):154-62. PubMed ID: 10064395
[TBL] [Abstract][Full Text] [Related]
37. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
38. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
[TBL] [Abstract][Full Text] [Related]
39. Lack of KBTBD4 Mutations in Molecularly Classified Brazilian Medulloblastomas.
Leal LF; Cavagna RO; Campanella NC; Mançano B; Almeida GC; Matsushita M; Almeida Junior CR; Saggioro F; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Neder L; Reis RM
J Neuropathol Exp Neurol; 2019 Sep; 78(9):788-790. PubMed ID: 31403685
[TBL] [Abstract][Full Text] [Related]
40. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
